NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
G1 Therapeutics, Inc.
Incyte Corporation
National Institutes of Health Clinical Center (CC)
TransThera Sciences (Nanjing), Inc.
Blanco, Dr Antonio Calles MD
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cyteir Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Sellas Life Sciences Group
Impact Therapeutics, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
TransThera Sciences (Nanjing), Inc.
Bristol-Myers Squibb
Sierra Oncology LLC - a GSK company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Aeglea Biotherapeutics
Gilead Sciences
G1 Therapeutics, Inc.
AbbVie
Stemcentrx
AbbVie
Amgen
Amgen
University of Alabama at Birmingham
Millennium Pharmaceuticals, Inc.
Teva Branded Pharmaceutical Products R&D, Inc.
National Cancer Institute, Naples
National Cancer Institute (NCI)
Bayer
University of Alabama at Birmingham
University of Chicago
ImmunoGen, Inc.
Ascenta Therapeutics